Riskpilot← Back to searchSign inGet full accessScandiBio Therapeutics AB
ABActiveOrg 5591059174Nanna Svartz Väg 4Research and experimental development on natural sciences and engineering · NACE 7210Est. 20170 employees
Revenue 2025
SEK 0
EBITDA margin
—
-47% vs 2024
Equity ratio
86.3%
Financial strength
Net profit 2025
SEK -16,2M
-47% vs 2024
| Revenue | SEK 0 | — |
| EBITDA | SEK -16,4M | -47% |
| Net profit | SEK -16,2M | -47% |
| Total assets | SEK 16,8M | +1% |
| Equity | SEK 14,5M | -8% |
| Employees | 0 | — |
Legal name
ScandiBio Therapeutics AB
Org number
5591059174
Legal form
Aktiebolag
NACE code
7210 · Research and experimental development on natural sciences and engineering
Founded
23 mars 2017
Share capital
SEK 87 627
Employees
0
VAT registered
Yes
Audit selected
No
Last report
2025-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen Firman tecknas två i förening av ledamöterna Dessutom har verkställande direktören rätt att teckna firman beträffande löpande förvaltningsåtgärder
Company purpose
Bolaget skall bedriva utveckling av läkemedel och därmed förenlig verksamhet.
Address
Nanna Svartz Väg 4
Email
olof.nord@scandibio.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Staff expenses | — | — | — | −66 | −131 |
| EBITDA | −5 026 | −2 446 | −2 394 | −11 130 | −16 415 |
| Depreciation & amort. | −0 | −0 | −0 | — | — |
| EBIT | −5 026 | −2 446 | −2 394 | −11 130 | −16 415 |
| Net financials | — | — | — | 97 | 193 |
| Profit before tax | −5 026 | −2 446 | −2 394 | −11 033 | −16 222 |
| Tax | −0 | −0 | −0 | — | — |
| Net profit | −5 026 | −2 446 | −2 394 | −11 033 | −16 222 |
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total assets | 15 351 | 9 385 | 7 191 | 16 657 | 16 804 |
| Equity | 11 603 | 9 157 | 6 763 | 15 730 | 14 509 |
| Long-term debt | 0 | 0 | 0 | — | — |
| Short-term debt | 3 748 | 229 | 429 | 926 | 2 295 |
| Total debt | 3 748 | 229 | 429 | 926 | 2 295 |
EBITDA margin
-1641518000.0%
This company
15.8%
Market median
-10389354530% vs market
20212025
Equity ratio
86.3%
This company
38.2%
Market median
+126% vs market
20212025
Return on equity
-111.8%
This company
18.4%
Market median
-708% vs market
20212025
Net profit margin
-1622223300.0%
This company
8.1%
Market median
-20027448248% vs market
20212025
Asset turnover
0.00×
This company
1.12×
Market median
-100% vs market
20212025
Debt / equity
0.16×
This company
0.62×
Market median
+74% vs market
20212025
- Annual report 2025Filed via Bolagsverket / SCB · Period 2025-01-01 – 2025-12-31
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
OG Chief Executive Officer | Chief Executive Officer | 2025 |
CF Chief Auditor | Chief Auditor | 2025 |
| Former (1) | ||
JN Chief Executive Officer | Chief Executive Officer | 2022 – 2025 |
| Name | Role | Member since |
|---|---|---|
| Current (6) | ||
| Board of Directors | 2022 | |
| Board of Directors | 2025 | |
| Chairman | 2022 | |
| Board of Directors | 2024 | |
| Board of Directors | 2022 | |
| Deputy Board Member | 2025 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of ScandiBio Therapeutics AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Olof Gustav Nord | Chief Executive Officer | 0 companies |
| Carl Fredrik Niring | Chief Auditor | 0 companies |
| Johan Nils Otto Järte | Chief Executive Officer | 0 companies |
| Jan Olof Sölve Borén | Board of Directors | 0 companies |
| Elin Desirée Almstedt | Board of Directors | 0 companies |
| Carl Erik Mathias Uhlén | Chairman | 0 companies |
| John Henrik Zetterberg | Board of Directors | 0 companies |
| Adil Mardinoglu | Board of Directors | 0 companies |
| David Bernhard Sonnek | Deputy Board Member | 0 companies |